Kbio Labs
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Kbio Labs distributes laboratory reagents, instruments, and equipment used in life-science research, supplying universities, hospitals, and research facilities.
It also provides ICT products and services, including video-security hardware, software, and integrated monitoring solutions such as smart-city surveillance systems. Listed on KOSDAQ, Korea's tech and small-cap board, the company operates two distinct business lines: a bio-distribution arm and an ICT arm built on video-security technology.
Summary is AI-generated and may contain errors · figures from DART filings
The bio-distribution business was acquired from Cure Bio's distribution division and has operated for over two decades, giving it an established customer base in the Korean life-science supply chain.
Kbio Labs in five facts
What does Kbio Labs do?
Kbio Labs distributes laboratory reagents, instruments, and equipment used in life-science research, supplying universities, hospitals, and research facilities.
Where is Kbio Labs listed and in which sector?
Kbio Labs (Korean name: 케이바이오랩스) trades under KRX code 038530 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Consumer Staples sector, Staples Retail.
How large is Kbio Labs?
Its market capitalisation was US$12.8M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Kbio Labs's latest annual revenue and operating profit?
For fiscal year 2025, Kbio Labs reported revenue of US$65.9M, operating profit of US$1.1M and a net loss of US$3.8M, per its annual report on DART (data retrieved from DART on 2026-09-08). Revenue was up 14.1% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-08
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Trading suspension liftedSep 18
- Report on securities held by executives/major shareholdersSep 4
- Report on large shareholdings (5% rule) (standard)Sep 4
- Trading suspension (share consolidation/split registration)
KOSDAQ trading in Kbio Labs Co., Ltd.'s common shares will be suspended from August 27, 2026 until the day before the new share certificates are listed, due to a share consolidation.
M&A · Aug 24 - Material event report (rights offering)
Kbio Labs disclosed a private placement (third-party allotment) to raise US$1.31M, about 9.8% of its market value.
Capital raise · Jul 6 - Trading suspension (share consolidation/split registration)M&A · Apr 9
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Kbio Labs reported consolidated results for FY2025: revenue of US$61M (+14.1% year on year), operating profit of US$1.25M (+125.3% year on year) and a net loss of US$2.49M.
Earnings · Feb 27